Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. – Merck.com

[ad_1] April 16, 2023 6:00 am ET PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target…